TY  - CONF
AU  - Miljić, Dragana
AU  - Pekić, Sandra
AU  - Doknić, Mirjana
AU  - Stojanović, Marko
AU  - Nikolić-Đurović, Marina
AU  - Medić-Stojanoska, Milica
AU  - Milošević, Verica
AU  - Šošić-Jurjević, Branka 
AU  - Ajdžanović, Vladimir
AU  - Jemuović, Zvezdana
AU  - Soldatović, Ivan
AU  - Popović, Vera
AU  - Petakov, Milan
PY  - 2018
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/5967
AB  - Previous studies reported increased prevalence of metabolic syndrome (MS) and
mortality rates from cardiovascular causes in hypopituitary patients. Fatty liver
disease was added recently to this unfavorable cardio-metabolic phenotype. We
studied the prevalence of MS and non-alcoholic fatty liver disease (NAFLD) in
unselected cohort of 282 hypopituitary patients (146 male), mean age 49.2G15.1
years, on standard replacement therapy (76.4% received l-thyroxin, 76%
hydrocortisone, 9.8% gonadal steroids, 4.6% desmopressin, 1.8% growth
hormone). Surrogat marker of MS, lipid acummulation product (LAP) was
calculated using gender specific formulas including waist circumference and
triglyceride level. Marker of NAFLD, fatty liver index (FLI) was calculated using
formula including body weight, height, waist circumference, triglyceride and
gamma glutamyl transferase levels. Hepatic steatosis was assessed by
ultrasonography and liver function tests. In this cross-sectional study, prevalence
of MS was 57.1% (using IDF) and 48.6% (with ATP III criteria). MS was more
common in females than males (IDF 63.2% vs 51.4%, PZ0.044; ATP III 54.4%
vs 43.2%, PZ0.059) and significantly associated with unreplaced hypogonadism
in female patients (PZ0.003). Statistically significant associations (P!0.001)
were found for MS and age, obesity, adult onset of hypopituitarism and NAFLD.
Prevalence of NAFLD in the cohort was 20.6%, based on ultrasonographic
features of hepatic steatosis, while in addition to this 7.1% had elevated liver
enzymes. For NAFLD, statistically significant associations were found with MS
(P!0.001), etiology of non-functioning pituitary macroadenoma (PZ0.006) and
growth hormone deficiency (PZ0.026). Hypopitutary patients with NAFLD had
more severe features of MS with significantly higher body mass index, waist
circumference, cholesterol and triglycerides, LAP and FLI, but lower HDL
compared to no-NAFLD patients (P!0.001). ROC analysis confirmed that LAP
and FLI were reliable markers of hepatic steatosis and functional hepatic
impairment resulting from NAFLD. MS is common in hypopituitarism, featuring
NAFLD in one third of hypopituitary patients with MS. Hypopituitary NAFLD
patients present with more severe MS and higher LAP and FLI indexes compared
to no-NAFLD patients. LAP and FLI are reliable markers of hepatic steatosis and
functional hepatic impairment, resulting from NAFLD. Complex interactions of
multiple pituitary hormone deficiencies and balance in their replacement are very
important for metabolic phenotype, as well as age, gender, obesity, adult onset
and etiology of hypopituitarism.
PB  - bioscientifica
C3  - 20th European Congress of Endocrinology; 2018 May 19-22; Barcelona, Spain
T1  - Clinical relevance of metabolic phenotype in hypopituitarism: what really matters?
DO  - 10.1530/endoabs.56.P821
ER  - 

@conference{
author = "Miljić, Dragana and Pekić, Sandra and Doknić, Mirjana and Stojanović, Marko and Nikolić-Đurović, Marina and Medić-Stojanoska, Milica and Milošević, Verica and Šošić-Jurjević, Branka  and Ajdžanović, Vladimir and Jemuović, Zvezdana and Soldatović, Ivan and Popović, Vera and Petakov, Milan",
year = "2018",
abstract = "Previous studies reported increased prevalence of metabolic syndrome (MS) and
mortality rates from cardiovascular causes in hypopituitary patients. Fatty liver
disease was added recently to this unfavorable cardio-metabolic phenotype. We
studied the prevalence of MS and non-alcoholic fatty liver disease (NAFLD) in
unselected cohort of 282 hypopituitary patients (146 male), mean age 49.2G15.1
years, on standard replacement therapy (76.4% received l-thyroxin, 76%
hydrocortisone, 9.8% gonadal steroids, 4.6% desmopressin, 1.8% growth
hormone). Surrogat marker of MS, lipid acummulation product (LAP) was
calculated using gender specific formulas including waist circumference and
triglyceride level. Marker of NAFLD, fatty liver index (FLI) was calculated using
formula including body weight, height, waist circumference, triglyceride and
gamma glutamyl transferase levels. Hepatic steatosis was assessed by
ultrasonography and liver function tests. In this cross-sectional study, prevalence
of MS was 57.1% (using IDF) and 48.6% (with ATP III criteria). MS was more
common in females than males (IDF 63.2% vs 51.4%, PZ0.044; ATP III 54.4%
vs 43.2%, PZ0.059) and significantly associated with unreplaced hypogonadism
in female patients (PZ0.003). Statistically significant associations (P!0.001)
were found for MS and age, obesity, adult onset of hypopituitarism and NAFLD.
Prevalence of NAFLD in the cohort was 20.6%, based on ultrasonographic
features of hepatic steatosis, while in addition to this 7.1% had elevated liver
enzymes. For NAFLD, statistically significant associations were found with MS
(P!0.001), etiology of non-functioning pituitary macroadenoma (PZ0.006) and
growth hormone deficiency (PZ0.026). Hypopitutary patients with NAFLD had
more severe features of MS with significantly higher body mass index, waist
circumference, cholesterol and triglycerides, LAP and FLI, but lower HDL
compared to no-NAFLD patients (P!0.001). ROC analysis confirmed that LAP
and FLI were reliable markers of hepatic steatosis and functional hepatic
impairment resulting from NAFLD. MS is common in hypopituitarism, featuring
NAFLD in one third of hypopituitary patients with MS. Hypopituitary NAFLD
patients present with more severe MS and higher LAP and FLI indexes compared
to no-NAFLD patients. LAP and FLI are reliable markers of hepatic steatosis and
functional hepatic impairment, resulting from NAFLD. Complex interactions of
multiple pituitary hormone deficiencies and balance in their replacement are very
important for metabolic phenotype, as well as age, gender, obesity, adult onset
and etiology of hypopituitarism.",
publisher = "bioscientifica",
journal = "20th European Congress of Endocrinology; 2018 May 19-22; Barcelona, Spain",
title = "Clinical relevance of metabolic phenotype in hypopituitarism: what really matters?",
doi = "10.1530/endoabs.56.P821"
}

Miljić, D., Pekić, S., Doknić, M., Stojanović, M., Nikolić-Đurović, M., Medić-Stojanoska, M., Milošević, V., Šošić-Jurjević, B., Ajdžanović, V., Jemuović, Z., Soldatović, I., Popović, V.,& Petakov, M.. (2018). Clinical relevance of metabolic phenotype in hypopituitarism: what really matters?. in 20th European Congress of Endocrinology; 2018 May 19-22; Barcelona, Spain
bioscientifica..
https://doi.org/10.1530/endoabs.56.P821

Miljić D, Pekić S, Doknić M, Stojanović M, Nikolić-Đurović M, Medić-Stojanoska M, Milošević V, Šošić-Jurjević B, Ajdžanović V, Jemuović Z, Soldatović I, Popović V, Petakov M. Clinical relevance of metabolic phenotype in hypopituitarism: what really matters?. in 20th European Congress of Endocrinology; 2018 May 19-22; Barcelona, Spain. 2018;.
doi:10.1530/endoabs.56.P821 .

Miljić, Dragana, Pekić, Sandra, Doknić, Mirjana, Stojanović, Marko, Nikolić-Đurović, Marina, Medić-Stojanoska, Milica, Milošević, Verica, Šošić-Jurjević, Branka , Ajdžanović, Vladimir, Jemuović, Zvezdana, Soldatović, Ivan, Popović, Vera, Petakov, Milan, "Clinical relevance of metabolic phenotype in hypopituitarism: what really matters?" in 20th European Congress of Endocrinology; 2018 May 19-22; Barcelona, Spain (2018),
https://doi.org/10.1530/endoabs.56.P821 . .

TY  - JOUR
AU  - Macut, Djuro
AU  - Božić Antić, Ivana
AU  - Bjekić-Macut, Jelica
AU  - Panidis, Dimitrios
AU  - Tziomalos, Konstantinos
AU  - Vojnović Milutinović, Danijela
AU  - Stanojlović, Olivera
AU  - Kastratović-Kotlica, Biljana
AU  - Petakov, Milan
AU  - Milić, Nataša
PY  - 2016
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/6332
AB  - OBJECTIVE: There is a need for a simple and accurate method for the assessment of cardiovascular risk in polycystic ovary syndrome (PCOS). Lipid accumulation product (LAP) is based on the assessment of waist circumference and serum triglycerides that yield an estimation of lipid overaccumulation. We aimed to determine whether LAP is associated with metabolic syndrome (MetS) in Caucasian women with PCOS. DESIGN: We studied 222 women with PCOS who were diagnosed using the Rotterdam criteria. In all the subjects and controls, LAP was determined and the MetS was assessed using three different international criteria, NCEP-ATP III, IDF, and JIS. ROC curve and logistic regression analyses were performed to determine and analyze associations with the MetS. RESULTS: In the study population the prevalence of MetS was 16.2–19.4%. The cut-off value of 25.9 determined that LAP has the strongest association with MetS whichever international criteria are used, followed by HDL (NCEP-ATP III and JIS) and glucose (IDF). CONCLUSIONS: LAP is used as an independent clinical indicator for MetS in our PCOS women of Caucasian origin. The high diagnostic accuracy of LAP is superseding the need for the use of multiple clinical indicators for the assessment of lipid accumulation as a prerequisite for diagnosis of metabolic and cardiovascular diseases in PCOS women.
PB  - Springer Nature
T2  - Hormones
T1  - Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome
VL  - 15
DO  - 10.1007/BF03401401
SP  - 35
EP  - 44
ER  - 

@article{
author = "Macut, Djuro and Božić Antić, Ivana and Bjekić-Macut, Jelica and Panidis, Dimitrios and Tziomalos, Konstantinos and Vojnović Milutinović, Danijela and Stanojlović, Olivera and Kastratović-Kotlica, Biljana and Petakov, Milan and Milić, Nataša",
year = "2016",
abstract = "OBJECTIVE: There is a need for a simple and accurate method for the assessment of cardiovascular risk in polycystic ovary syndrome (PCOS). Lipid accumulation product (LAP) is based on the assessment of waist circumference and serum triglycerides that yield an estimation of lipid overaccumulation. We aimed to determine whether LAP is associated with metabolic syndrome (MetS) in Caucasian women with PCOS. DESIGN: We studied 222 women with PCOS who were diagnosed using the Rotterdam criteria. In all the subjects and controls, LAP was determined and the MetS was assessed using three different international criteria, NCEP-ATP III, IDF, and JIS. ROC curve and logistic regression analyses were performed to determine and analyze associations with the MetS. RESULTS: In the study population the prevalence of MetS was 16.2–19.4%. The cut-off value of 25.9 determined that LAP has the strongest association with MetS whichever international criteria are used, followed by HDL (NCEP-ATP III and JIS) and glucose (IDF). CONCLUSIONS: LAP is used as an independent clinical indicator for MetS in our PCOS women of Caucasian origin. The high diagnostic accuracy of LAP is superseding the need for the use of multiple clinical indicators for the assessment of lipid accumulation as a prerequisite for diagnosis of metabolic and cardiovascular diseases in PCOS women.",
publisher = "Springer Nature",
journal = "Hormones",
title = "Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome",
volume = "15",
doi = "10.1007/BF03401401",
pages = "35-44"
}

Macut, D., Božić Antić, I., Bjekić-Macut, J., Panidis, D., Tziomalos, K., Vojnović Milutinović, D., Stanojlović, O., Kastratović-Kotlica, B., Petakov, M.,& Milić, N.. (2016). Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome. in Hormones
Springer Nature., 15, 35-44.
https://doi.org/10.1007/BF03401401

Macut D, Božić Antić I, Bjekić-Macut J, Panidis D, Tziomalos K, Vojnović Milutinović D, Stanojlović O, Kastratović-Kotlica B, Petakov M, Milić N. Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome. in Hormones. 2016;15:35-44.
doi:10.1007/BF03401401 .

Macut, Djuro, Božić Antić, Ivana, Bjekić-Macut, Jelica, Panidis, Dimitrios, Tziomalos, Konstantinos, Vojnović Milutinović, Danijela, Stanojlović, Olivera, Kastratović-Kotlica, Biljana, Petakov, Milan, Milić, Nataša, "Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome" in Hormones, 15 (2016):35-44,
https://doi.org/10.1007/BF03401401 . .

TY  - JOUR
AU  - Macut, Đuro P
AU  - Vojnović-Milutinović, Danijela
AU  - Bozić, Ivana B
AU  - Matić, Gordana
AU  - Brkljačić, Jelena
AU  - Panidis, Dimitrios
AU  - Petakov, Milan S
AU  - Spanos, Nikolaos
AU  - Bjekić, Jelica
AU  - Stanojlović, Olivera P
AU  - Petrović-Milinković, Anđela
AU  - Radojicić, Zoran A
AU  - Damjanović, Svetozar S
PY  - 2010
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/1402
AB  - Glucocorticoid receptor (GR) transduces the glucocorticoid (GC) signal that could lead to metabolic derangements depending on the tissue responsiveness to GC. We aimed to investigate possible causative relation of the GR functional properties in peripheral blood mononuclear cells of women with polycystic ovary syndrome (PCOS), with their clinical and biochemical characteristics. Thirty women with PCOS [mean age: 26.5 +/- A 5.1 years, mean body mass index (BMI) 24.5 +/- A 5 kg/m(2)], and thirty respective controls were analyzed for the number of GR sites per cell (B (max)), apparent equilibrium dissociation constant (K (d)), and binding potency (GR potency). A strong association between B (max) and K (d) (r = 0.70, P < 0.0001), and GR potency with age (r = 0.49, P = 0.009) was observed in PCOS women. The multiple regression analyses within the PCOS group revealed that independent predictors for K (d) were BMI, total cholesterol, and dehydroepiandrosterone-sulfate (DHEA-S) (r = 0.58, P = 0.038), while for GR potency (r = 0.687, P = 0.013) were age, BMI, DHEA-S, and basal cortisol concentration. The results suggest that PCOS pathophysiology may be related to alterations of a cross stalk between glucocorticoid signaling, age, and metabolic parameters. These findings should be further explored in studies on the role of GR in PCOS-related metabolic derangements.
T2  - Endocrine
T1  - Age, body mass index, and serum level of DHEA-S can predict glucocorticoid receptor function in women with polycystic ovary syndrome
IS  - 1
VL  - 37
EP  - 134
UR  - https://hdl.handle.net/21.15107/rcub_ibiss_1402
ER  - 

@article{
author = "Macut, Đuro P and Vojnović-Milutinović, Danijela and Bozić, Ivana B and Matić, Gordana and Brkljačić, Jelena and Panidis, Dimitrios and Petakov, Milan S and Spanos, Nikolaos and Bjekić, Jelica and Stanojlović, Olivera P and Petrović-Milinković, Anđela and Radojicić, Zoran A and Damjanović, Svetozar S",
year = "2010",
abstract = "Glucocorticoid receptor (GR) transduces the glucocorticoid (GC) signal that could lead to metabolic derangements depending on the tissue responsiveness to GC. We aimed to investigate possible causative relation of the GR functional properties in peripheral blood mononuclear cells of women with polycystic ovary syndrome (PCOS), with their clinical and biochemical characteristics. Thirty women with PCOS [mean age: 26.5 +/- A 5.1 years, mean body mass index (BMI) 24.5 +/- A 5 kg/m(2)], and thirty respective controls were analyzed for the number of GR sites per cell (B (max)), apparent equilibrium dissociation constant (K (d)), and binding potency (GR potency). A strong association between B (max) and K (d) (r = 0.70, P < 0.0001), and GR potency with age (r = 0.49, P = 0.009) was observed in PCOS women. The multiple regression analyses within the PCOS group revealed that independent predictors for K (d) were BMI, total cholesterol, and dehydroepiandrosterone-sulfate (DHEA-S) (r = 0.58, P = 0.038), while for GR potency (r = 0.687, P = 0.013) were age, BMI, DHEA-S, and basal cortisol concentration. The results suggest that PCOS pathophysiology may be related to alterations of a cross stalk between glucocorticoid signaling, age, and metabolic parameters. These findings should be further explored in studies on the role of GR in PCOS-related metabolic derangements.",
journal = "Endocrine",
title = "Age, body mass index, and serum level of DHEA-S can predict glucocorticoid receptor function in women with polycystic ovary syndrome",
number = "1",
volume = "37",
pages = "134",
url = "https://hdl.handle.net/21.15107/rcub_ibiss_1402"
}

Macut, Đ. P., Vojnović-Milutinović, D., Bozić, I. B., Matić, G., Brkljačić, J., Panidis, D., Petakov, M. S., Spanos, N., Bjekić, J., Stanojlović, O. P., Petrović-Milinković, A., Radojicić, Z. A.,& Damjanović, S. S.. (2010). Age, body mass index, and serum level of DHEA-S can predict glucocorticoid receptor function in women with polycystic ovary syndrome. in Endocrine, 37(1).
https://hdl.handle.net/21.15107/rcub_ibiss_1402

Macut ĐP, Vojnović-Milutinović D, Bozić IB, Matić G, Brkljačić J, Panidis D, Petakov MS, Spanos N, Bjekić J, Stanojlović OP, Petrović-Milinković A, Radojicić ZA, Damjanović SS. Age, body mass index, and serum level of DHEA-S can predict glucocorticoid receptor function in women with polycystic ovary syndrome. in Endocrine. 2010;37(1):null-134.
https://hdl.handle.net/21.15107/rcub_ibiss_1402 .

Macut, Đuro P, Vojnović-Milutinović, Danijela, Bozić, Ivana B, Matić, Gordana, Brkljačić, Jelena, Panidis, Dimitrios, Petakov, Milan S, Spanos, Nikolaos, Bjekić, Jelica, Stanojlović, Olivera P, Petrović-Milinković, Anđela, Radojicić, Zoran A, Damjanović, Svetozar S, "Age, body mass index, and serum level of DHEA-S can predict glucocorticoid receptor function in women with polycystic ovary syndrome" in Endocrine, 37, no. 1 (2010),
https://hdl.handle.net/21.15107/rcub_ibiss_1402 .